SEARCH

SEARCH BY CITATION

References

  • 1
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 26012614.
  • 2
    Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42: S70S72.
  • 3
    Lowance D, Neumayer H-H, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 14621470.
  • 4
    Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998; 72: 59275936.
  • 5
    Chou S, Lurain NS, Weinberg A, et al. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob Agents Chemother 1999; 43: 15001502.
  • 6
    Castor J, Cook L, Corey L, Jerome KR. Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. J Clin Microbiol 2007; 45: 26812683.
  • 7
    Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23: 689712.
  • 8
    van der Beek MT, Marijt EW, Vossen AC, et al. Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients. Antivir Ther 2012; 17: 4551.
  • 9
    Dolan A, Cunningham C, Hector RD, et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol 2004; 85: 13011312.
  • 10
    van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: Comparison of treatment failure and antiviral resistance. Transplantation 2010; 89: 320326.
  • 11
    Sommadossi JP, Carlisle R. Toxicity of 3’-azido-3’-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother 1987; 31: 452454.
  • 12
    Chou S, Van Wechel LC, Lichy HM, Marousek GI. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005; 49: 27102715.
  • 13
    Springer KL, Chou S, Li S, et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005; 43: 208213.
  • 14
    Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002; 185: 162169.
  • 15
    Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008; 18: 233246.
  • 16
    Almyroudis NG, Jakubowski A, Jaffe D, et al. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2007; 9: 286294.
  • 17
    Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: Implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother 2009; 63: 600608.
  • 18
    Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002; 21: 127482.
  • 19
    Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999; 68: 12721279.
  • 20
    Gratama JW, Boeckh M, Nakamura R, et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: A prospective multicenter study. Blood 2010; 116: 16551662.
  • 21
    Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188: 3239.
  • 22
    Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 12051213.
  • 23
    Couzi L, Helou S, Bachelet T, et al. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012; 12: 202209.
  • 24
    Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010; 54: 23712378.
  • 25
    Chou S, Van Wechel LC, Marousek GI. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007; 196: 9194.
  • 26
    Lurain NS, Spafford LE, Thompson KD. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol 1994; 68: 44274431.
  • 27
    Alain S, Hantz S, Scieux C, et al. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. J Med Virol 2004; 73: 566573.
  • 28
    Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7: 166170.
  • 29
    Boutolleau D, Deback C, Bressollette-Bodin C, et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 2009; 81: 174179.
  • 30
    Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186: 760768.
  • 31
    Hantz S, Garnier-Geoffroy F, Mazeron M-C, et al. Drug-resistant cytomegalovirus in transplant recipients: A French cohort study. J Antimicrob Chemother 2010; 12: 26282640.
  • 32
    Martin M, Goyette N, Ives J, Boivin G. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J Clin Virol 2010; 47: 321324.
  • 33
    Marfori JE, Exner MM, Marousek GI, Chou S, Drew WL. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007; 38: 120125.
  • 34
    Erice A, Gil-Roda C, Perez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175: 10871092.
  • 35
    Scott GM, Isaacs MA, Zeng F, Kesson AM, Rawlinson WD. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J Med Virol 2004; 74: 8593.
  • 36
    Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009; 14: 697704.
  • 37
    Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176: 6977.
  • 38
    Reddy AJ, Zaas AK, Hanson KE, Palmer SM. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: Treatment and outcome. J Heart Lung Transplant 2007; 26: 12861292.
  • 39
    Hanson MN, Preheim LC, Chou S, Talarico CL, Biron KK, Erice A. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother 1995; 39: 12041205.
  • 40
    Erice A, Borrell N, Li W, Miller WJ, Balfour HH, Jr. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 1998; 178: 531534.
  • 41
    Bourgeois C, Sixt N, Bour JB, Pothier P. Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus. J Virol Methods 1997; 67: 167175.
  • 42
    Baldanti F, Silini E, Sarasini A, et al. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol 1995; 69: 796800.
  • 43
    Mendez JC, Sia IG, Tau KR, et al. Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation 1999; 67: 755757.
  • 44
    Chou S, Meichsner CL. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrob Agents Chemother 2000; 44: 183185.
  • 45
    Baldanti F, Michel D, Simoncini L, et al. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res 2002; 54: 5967.
  • 46
    Faizi Khan R, Mori S, Eizuru Y, Kumura Ishii K, Minamishima Y. Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. Antiviral Res 1998; 40: 95103.
  • 47
    Hantz S, Michel D, Fillet AM, et al. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Antimicrob Agents Chemother 2005; 49: 15801583.
  • 48
    Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176: 786789.
  • 49
    Baldanti F, Underwood MR, Talarico CL, et al. The Cys607[RIGHTWARDS ARROW]Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agents Chemother 1998; 42: 444446.
  • 50
    Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189: 16151618.